Cancer Research and Treatment

Im Il Na

5 Articles

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy: Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang; Cancer Res Treat. 2017;49(3):807-815. Published online January 18, 2017; DOI: https://doi.org/10.4143/crt.2016.326

Purpose
While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer.
Materials and Methods
Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first-line S-1 and cisplatin chemotherapy were enrolled. Serum tumor markers were measured at baseline and after the first cycle of chemotherapy.
Results
Among a total of 104 patients, 80 (77%) had elevated baseline tumor markers (69 with CA 19-9 elevation and 40 with CEA). A decline ≥ 30% of the elevated tumor marker level after the first cycle of chemotherapy conferred an improved time to progression (TTP), overall survival (OS), and better chemotherapy response. Multivariate analysis revealed tumor marker decline as an independent positive prognostic factor of TTP (adjusted hazard ratio [HR], 0.44; p=0.003) and OS (adjusted HR, 0.37; p < 0.001). Subgroup analysis revealed similar results in each group of patients with CA 19-9 elevation and CEA elevation. In addition, elevated baseline CEA was associated with poor survival in both univariate and multivariate analysis.
Conclusion
Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.

Citations

Citations to this article as recorded by

Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari
Cancer Treatment and Research Communications.2021; 28: 100431. CrossRef
Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei—A Novel Treatment Approach
Aruna Prabhu, Andreas Brandl, Satoshi Wakama, Shouzou Sako, Haruaki Ishibashi, Akiyoshi Mizumoto, Nobuyuki Takao, Kousuke Noguchi, Shunsuke Motoi, Masumi Ichinose, Yang Liu, Yutaka Yonemura
Cancers.2020; 12(8): 2212. CrossRef
Clinical and Translational Research Challenges in Biliary Tract Cancers
Angela Lamarca, Melissa Frizziero, Mairéad G. McNamara, Juan W. Valle
Current Medicinal Chemistry.2020; 27(29): 4756. CrossRef
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Min su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee, Yong-Tae Kim
BMC Cancer.2019;[Epub] CrossRef
Efficacy of interventional therapy and effect on inflammatory factors in patients with gastric cancer after chemotherapy
Puzhao Wu, Jing Wang
Oncology Letters.2019;[Epub] CrossRef
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Kensaku Noguchi, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Kazunaga Ishigaki, Ryunosuke Hakuta, Tsuyoshi Takeda, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Minoru Tada
Cancer Chemotherapy and Pharmacology.2017; 80(6): 1105. CrossRef

12,504 View
201 Download
7 Web of Science
6 Crossref

Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures: Jung Ho Yoon, Min Soo Kim, Eun Hee Kook, Se Han Ahn, Se Young Jeong, Min Sung Han, Jung Kwon Huh, Hye Jin Kang, Im Il Na, Soo Youn Cho, Sang Bum Kim, Baek Yeol Ryoo, Sung Hyun Yang; Cancer Res Treat. 2008;40(3):145-150. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.145

Abstract PDF PubReader ePub

Primary gastric choriocarcinoma (PGC) is a rare tumor, and its pathogenesis is still uncertain. Most PGCs have been reported to possess an adenocarcinoma component of variable extent, and pure PGC is especially rare. The diagnosis of PGC is confirmed by exhibition of choriocarcinomatous components on biopsy and exhibition of β-hCG positive cell on immunohistochemical stain and elevation of the serum β-hCG. Moreover it must be confirmed that no other site including gonads displays any tumor masses. The PGC tends to be more invasive and to have early metastasis. The median survival is known to be less than several months. We report two cases. The first case was a 62 year-old man who was diagnosed as advanced gastric cancer (AGC) by endoscopic biopsy with hepatic metasasis and received palliative chemotherapy with modified FOLFOX regimen and Genexol plus cisplatin regimen. He underwent subtotal gastrectomy due to perforation of the stomach during chemotherapy. On post-operative biopsy, He was re-diagnosed as PGC and received another palliative chemotherapy modified FOLFIRI, BEP, EMACO, VIP. However, multiple liver metastases were aggravated, and also serum AFP level increased. Ultimately, the paient died 10 months after initial diagnosis. Another case was a 45 year-old man. On endoscopic biopsy, he was diagnosed as AGC of adenocarcinoma. On Chest and Abdomen CT, multiple pulmonary and hepatic metastasis were also confirmed. On liver biopsy, He was diagnosed as PGC. The immunohistochemical stains were performed and the results were cytokeratin positive, EMA negative and β-hCG weak positive. The serum β-hCG level was highly elevated. BEP, VIP and EMA/CO combination therapy were administered, but he died at 12th months after the initial diagnosis.

Citations

Citations to this article as recorded by

Morphological and molecular pathological features of the breast carcinoma with choriocarcinomatous features: A case report and a literature review
Jingchun Xu, Yi Xu, Cheng Xu, Cong Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: a rare primary gastric choriocarcinoma revealed on 18F-FDG PET/CT
Yi Zhao, Wei Diao, Suping Li, Mengxi Yang, Zhuzhong Cheng
Frontiers in Oncology.2023;[Epub] CrossRef
Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report
Nicole M. Iñiguez-Ariza, Dalia Cuenca, Juvenal Franco-Granillo, Alberto Villalobos-Prieto, Janet Pineda-Díaz, Javier Baquera-Heredia
Journal of Medical Case Reports.2022;[Epub] CrossRef
Primary gastric choriocarcinoma: A case report
Zhang Xusheng, Yan Yuke, Meng Yun, Guo Huijun, Peng Jiangshan, Du Xueqin, Yang Xiaojun
Frontiers in Surgery.2022;[Epub] CrossRef
Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
Jina Yun, Sang W Lee, Sung H Lim, Se H Kim, Chan K Kim, Seong K Park
World Journal of Clinical Cases.2020; 8(21): 5334. CrossRef
Primary Gastric Choriocarcinoma Coexisting with Adenocarcinoma
Joo Hyun Lee, Jeong Kyun Lee, Dong Baek Kang
The Korean Journal of Gastroenterology.2019; 73(6): 350. CrossRef
Primary gastric choriocarcinoma with multiple metastases – A case report and literature review of carcinogenesis
Yiqin Xiong, Michelle X. Yang
Human Pathology: Case Reports.2019; 18: 200330. CrossRef
Collision tumor of choriocarcinoma and small cell carcinoma of the stomach: A case report
Shuichi Fukuda, Yoshinori Fujiwara, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Hajime Ishikawa, Masanori Tsujie, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
International Journal of Surgery Case Reports.2017; 37: 216. CrossRef
Primary Choriocarcinoma of the Stomach. A Case Report and Review of the Literature
Rahul Raghavapuram, Fadl H Veerankutty, M Anandakumar
Indian Journal of Surgical Oncology.2016; 7(1): 119. CrossRef
A Case of a Duodenal Papilla Adenosquamous Carcinoma with Trophoblastic Differentiation
Daichi KITAGUCHI, Shingo SAKASHITA, Shinji HASHIMOTO, Tatsuya ODA, Nobuhiro OHKOHCHI, Masayuki NOGUCHI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2016; 77(6): 1440. CrossRef
Biochemical remission by chemoradiotherapy in male mediastinal choriocarcinoma with diffuse lung metastasis: A case report
JING ZHANG, ZHI-JUN WANG, BIN YANG, YOU-YING WEI, LING YANG, YANG HU, YAN-PING HU
Oncology Letters.2016; 11(4): 2615. CrossRef
Primary gastric choriocarcinoma: A rare case
Vilma Florença Martins, Filipa Moreno, J. Ramón Vizcaíno, Jorge Santos
International Journal of Surgery Case Reports.2015; 14: 44. CrossRef
Resectable Primary Gastric Choriocarcinoma with Solitary Synchronous Liver Metastasis
Masafumi Tomita, Eisei Nishino, Tomoya Takami, Yu Oshima, Kotaro Hatano, Satoshi Wakama, Hayato Furue, Yasuhiro Matsuda, Naoki Kataoka, Tomoyuki Yamaguchi
The Japanese Journal of Gastroenterological Surgery.2015; 48(6): 488. CrossRef
Endometrioid adenocarcinoma with choriocarcinomatous differentiation: A case report and review of the literature
MITSUAKI ISHIDA, HIDETOSHI OKABE
Oncology Letters.2013; 6(3): 655. CrossRef
Gastric adenocarcinoma with choriocarcinomatous and hepatoid differentiation
Seong Wook Hwang, Sun Jae Lee, Po Eun Park, Mee Seon Kim, Han‐Ik Bae
Basic and Applied Pathology.2012; 5(1): 22. CrossRef
Pathological Complete Response and Two-year Disease-free Survival in a Primary Gastric Choriocarcinoma Patient with Advanced Liver Metastases Treated with Germ Cell Tumor-based Chemotherapy: A Case Report
Y. Waseda, Y. Komai, A. Yano, Y. Fujii, N. Noguchi, K. Kihara
Japanese Journal of Clinical Oncology.2012; 42(12): 1197. CrossRef
Gastric cancer with choriocarcinoma and yolk sac tumor components: Case report
Nobuo Satake, Motoya Chikakiyo, Toshiyuki Yagi, Yasuhiro Suzuki, Takanori Hirose
Pathology International.2011; 61(3): 156. CrossRef
A Coexistent Case of Primary Gastric Choriocarcinoma and Alpha Fetoprotein-producing Gastric Cancer which Caused Rapid Postoperative Progression
Naoya Sasaki, Yoshiharu Shirakata, Hisashi Shinohara, Kazumi Itoi, Atsuhiko Maki, Yoshifumi Mizuno, Rokuro Mimura, Koushou Takasu
The Japanese Journal of Gastroenterological Surgery.2011; 44(12): 1535. CrossRef

11,871 View
62 Download
18 Crossref

Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer: Yo Han Joh, Tae You Kim, Im Il Na, Do Youn Oh, Byung Su Kim, Jee Hyun Kim, Do Yeun Kim, Se Hoon Lee, Chul Gyu Yoo, Choon Taek Lee, Young Whan Kim, Dae Seog Heo, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim; Cancer Res Treat. 2001;33(5):373-376. Published online October 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.5.373

Abstract PDF

PURPOSE
Platinum-based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in patients with advanced non-small cell lung cancer (NSCLC). We performed a phase II trial in order to evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine (Navelbine) and cisplatin in advanced NSCLC.
MATERIALS AND METHODS
Patients with previously untreated, unresectable stage IIIB or IV NSCLC with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous vinorelbine 25 mg/m2, on day 1 and 8, and intravenous cisplatin 80 mg/m2 on day 1; this cycle was repeated every three weeks.
RESULTS
A total of 33 patients were enrolled in the study between July 1999 and Feb 2000. Of the 30 patients deemed eligible for analysis, thirteen patients achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 toxicities were anemia in 1.5%, leukopenia in 4.5%, nausea/vomiting in 2.3%, alopecia in 13.3%, and neurotoxicity in 3.3%.
CONCLUSION
The combination of vinorelbine and cisplatin chemotherapy seems to be active and fairly tolerable in patients with advanced NSCLC.

Citations

Citations to this article as recorded by

Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
Yibo Zhao, Yu Dong, Shu Xing, Xueqi Fu
European Journal of Inflammation.2018;[Epub] CrossRef

4,498 View
23 Download
1 Crossref

Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea: Se Hoon Lee, Hee Jeoung Cha, Jee Hyun Kim, Im Il Na, Jun Hee Lee, Hark Kyun Kim, Keun Seok Lee, Won Sup Lee, Chong Jai Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(6):1022-1030.

Abstract PDF: PURPOSE
The clinicopathologic features and prognostic factors of gastrointestinal leiomyosarcoma have been a source of controversy.
MATERIALS AND METHODS
A retrospective study was made of 91 incident cases of gastrointestinal leiomyosarcoma from 1979 to 1998 to identify clinicopathologic features and prognostic factors.
RESULTS
The median age of study subjects was 56 years and 58.2% was male. Tumors consisted of 2 esophagus, 39 stomach, 38 small bowel, 12 large bowel leiomyosarcoma. Mean size of the tumors was 10.9 cm and 52.9% of them was larger than 10 cm. The tumors were classified as localized stage (42 cases), advanced stage (21 cases), and metastatic stage (28 cases). Again, the tumors were classified as low grade (48 cases) and high grade (18 cases). Median overall survival was 37.4 months and median disease-free survival was 28.2 months. In univariate analysis, the significant factors affecting the overall survival of patients with leiomyosarcoma were stage, size greater than 10 cm, performance status, and histologic grade. In multivariate analysis, stage, performance status, and histologic grade were independent factors affecting the overall survival. In univariate analysis, the significant factors affecting the disease-free survival were stage, performance status, and histologic grade. In multivariate analysis, histologic grade was the only independent factor affecting the disease-free survival.
CONCLUSION
Stage, performance status, and histologic grade were independent factors affecting the overall survival. Histologic grade was independent factor affecting the disease-free survival.

2,779 View
14 Download

Prognostic Factor Analysis of Aggressive Non - Hodgkin's Lymphoma Based on International Prognostic Index Model: Min Hee Ryu, Young Iee Park, Hark Kyun Kim, Dae Ho Lee, Joo Young Jeong, Dong Wan Kim, Im Il Na, Ji Hyun Kim, Se Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seon Yang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(6):1269-1278.

Abstract PDF: PURPOSE
International Prognostic Index Model (IPIM) in aggressive non-Hodgkin's lymphoma was published and accepted generally as a better predictive model for prognosis. This study was undertaken to identify prognostic factors of aggressive non- Hodgkin's lymphoma and usefulness of IPIM in Korea.
MATERIALS AND METHODS
Previously untreated, pathologically proven 226 aggressive non-Hodgkin's lymphoma patients who were treated with CHOP or COP-BLAM V between 1986 and 1995 in Seoul National University Hospital were evaluated for clinical features predictive of overall survival.
RESULTS
Complete response (CR) was reached in 76% of all patients. With a median follow-up of 62 months, 5-year disease free survival of complete reponders was 67% and 5-year overall survival of all patients was 54%. In a univriate analysis, age, ECOG performance status, Ann Arbor stage, histologic subtype, bone marrow involvement, bulkiness, serum LDH level and number of extranodal involvement were significant prognostic factors for CR and survival (p<0.05). Of these, by multivariate analysis, age(RR 0.4, 95% CI 0.2~0.9) alone was a independent prognostic factor for CR. For disease free survival, no independent prognostic factor was found. For overall survival, Ann Arbor stage (RR 1.7, 95% CI 1.1~2.8), age (RR 1.7, 95% CI 1.1~2.6), Histologic subtype (RR 1.7, 95% CI 1.1~2.8), serum LDH level (RR 1.7, 95% CI 1.1~2.6) and bone marrow involvement (RR 1.8, 95% CI 1.0~3.1) were independent prognostic factors. According to risk group of IPIM, 5-year overall survival rate was 72% in low risk group, 46% in low intermediate risk group, 32% in high intermediate risk group, respectively, and median survival of high risk group was 12 months (RR 1, 2.3, 4.3, 6.4 respectively).
CONCLUSION
IPIM is a useful model for identifying poor prognostic groups in aggressive non-Hodgkin's lymphoma.

3,149 View
17 Download

Author index